Concurrent vaccination with two distinct vaccine platforms targeting the same antigen generates phenotypically and functionally distinct T-cell populations |
| |
Authors: | Amanda L Boehm Jack Higgins Alex Franzusoff Jeffrey Schlom James W Hodge |
| |
Institution: | (1) Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 10 Center Drive, Room 8B09, MSC 1750, Bethesda, MD 20892, USA;(2) GlobeImmune, Inc., 1450 Infinite Dr., Louisville, CO 80027, USA; |
| |
Abstract: | Purpose Studies comparing two or more vaccine platforms have historically evaluated each platform based on its ability to induce an
immune response and may conclude that one vaccine is more efficacious than the other(s), leading to a recommendation for development
of the more effective vaccine for clinical studies. Alternatively, these studies have documented the advantages of a diversified
prime and boost regimen due to amplification of the antigen-specific T-cell population. We hypothesize here that two vaccine
platforms targeting the same antigen might induce shared and distinct antigen-specific T-cell populations, and examined the
possibility that two distinct vaccines could be used concomitantly. |
| |
Keywords: | |
本文献已被 SpringerLink 等数据库收录! |
|